#United States #New York #Class Action #Gross Law Firm #Capricor Therapeutics

Notice to Capricor Therapeutics Investors

The Gross Law Firm has recently issued an important notice to the shareholders of Capricor Therapeutics, Inc., which trades on NASDAQ under the ticker symbol CAPR. This communication serves as a reminder for investors who acquired shares during a specified class period to be aware of a class action lawsuit and the associated deadlines they need to heed.

Class Period Details

Shareholders who purchased shares of Capricor from October 9, 2024, until July 10, 2025, are encouraged to connect with the Gross Law Firm to understand their potential to become a lead plaintiff. It’s essential to mention that being a lead plaintiff is not a requirement for participating in any potential recovery from the lawsuit.

Allegations against Capricor Therapeutics

The allegations outlined in the legal complaint assert that the defendants provided investors with misleading information regarding Capricor's lead cell therapy drug, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Notably, the complaint highlights claims that included Capricor's assurance of acquiring a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).

However, the firm claims, simultaneously, that Capricor disseminated false and misleading statements while omitting crucial facts about the drug’s safety and efficacy as evidenced over four years in its Phase 2 HOPE-2 clinical trial.

Significant Price Drop Following FDA News

On July 11, 2025, Capricor disclosed the receipt of a Complete Response Letter (CRL) from the FDA, highlighting that the application did not meet established statutory evidence requirements. Furthermore, the CRL pointed to additional data needed in the Chemistry, Manufacturing, and Controls section of the application. Following this announcement, Capricor's stock price suffered a substantial decline, dropping from $11.40 per share on July 10, 2025, to $7.64 per share the following day.

Important Deadlines for Shareholders

The deadline for shareholders to register for this class action lawsuit is set for September 15, 2025. It is vital for impacted investors not to postpone their registration to participate in the case, as timely action can facilitate their involvement in any financial recovery.

Once shareholders register, they will be enrolled in a portfolio monitoring system that offers status updates throughout the case's progression. Notably, there is no cost or obligation for shareholders to engage in this class action.

Choosing the Gross Law Firm

The Gross Law Firm holds a reputable standing as a nationally recognized class action law firm. Their mission remains focused on safeguarding the rights of investors who have faced hardships due to misleading information or unethical practices by corporations. Committed to enhancing corporate responsibility and transparency, the firm strives to secure reparations for investors whose losses stem from deceptive actions that inflated a company's stock value unjustly.

Contact Information

Investors wishing to connect with the Gross Law Firm for more information or to register can reach out via the following:

• - Address: The Gross Law Firm,

15 West 38th Street, 12th floor,
New York, NY, 10018

• - Email: [email protected]
• - Phone: (646) 453-8903

This notification serves not only as a call to action for shareholders of Capricor Therapeutics but also as a reminder of the ongoing importance of vigilance when engaging with publicly traded companies. Investors should ensure they remain informed and proactive about their rights and protections under the law.